Izadifard et al. found that acute myeloid leukemia-M3 (AML-M3) patients have higher PVT1 expression than normal controls, and high-risk AML-M3 patients have higher expression levels of PVT1 than low- and intermediate-risk patients [315]. Here, PVT1 is linked to acute promyelocytic leukemia.